ArticleBMC genomics2012
The stable traits of melanoma genetics: an alternate approach to target discovery.
Article in BMC genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?Cancer cell international · 2024Review
- Network-based identification of key master regulators associated with an immune-silent cancer phenotype.Briefings in bioinformatics · 2021Article
- Human sample authentication in biomedical research: comparison of two platforms.Scientific reports · 2021Article
- Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.Journal of translational medicine · 2020Article
- Monoallelic expression in melanoma.Journal of translational medicine · 2019Article
- Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy.Frontiers in immunology · 2019Review
- The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.British journal of cancer · 2018Article
- Immune oncology, immune responsiveness and the theory of everything.Journal for immunotherapy of cancer · 2018Article
- Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.Cancer immunology research · 2016Article
- Checkpoint Inhibitors and Their Application in Breast Cancer.Breast care (Basel, Switzerland) · 2016Review
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Journal of translational medicine · 2015Article
- A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.Oncotarget · 2015Article
- Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours.Human genomics · 2015Article
- The immune-related role of BRAF in melanoma.Molecular oncology · 2015Article
- Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.British journal of cancer · 2014Article
- Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.The Journal of investigative dermatology · 2014Article
- Melanoma NOS1 expression promotes dysfunctional IFN signaling.The Journal of clinical investigation · 2014Article
- CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.British journal of cancer · 2013Article
- IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.British journal of cancer · 2013Article
- Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 5 countries.
Funding
Abstract
backgroundThe weight that gene copy number plays in transcription remains controversial; although in specific cases gene expression correlates with copy number, the relationship cannot be inferred at the global level. We hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs) should be critical for oncogenesis and their expression most frequently influenced by their respective copy number.
resultsFunctional interpretation of 3,030 transcripts concordantly expressed (Pearson's correlation coefficient p-value < 0.05) by CMs and TMs confirmed an enrichment of functions crucial to oncogenesis. Among them, 968 were expressed according to the transcriptional efficiency predicted by copy number analysis (Pearson's correlation coefficient p-value < 0.05). We named these genes, "genomic delegates" as they represent at the transcriptional level the genetic footprint of individual cancers. We then tested whether the genes could categorize 112 melanoma metastases. Two divergent phenotypes were observed: one with prevalent expression of cancer testis antigens, enhanced cyclin activity, WNT signaling, and a Th17 immune phenotype (Class A). This phenotype expressed, therefore, transcripts previously associated to more aggressive cancer. The second class (B) prevalently expressed genes associated with melanoma signaling including MITF, melanoma differentiation antigens, and displayed a Th1 immune phenotype associated with better prognosis and likelihood to respond to immunotherapy. An intermediate third class (C) was further identified. The three phenotypes were confirmed by unsupervised principal component analysis.
conclusionsThis study suggests that clinically relevant phenotypes of melanoma can be retraced to stable oncogenic properties of cancer cells linked to their genetic back bone, and offers a roadmap for uncovering novel targets for tailored anti-cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.